The MHRA has reminded prescribers of the increased risk of rhabdomyolysis when systemic fusidic acid (Fucidin) is used at the same time as a statin. The exact mechanism of this interaction is unknown and it could therefore occur with some, or all, statins.
The MHRA has issued the following advice:
- Systemic fusidic acid should not be given with statins.
- When the use of systemic fusidic acid is essential, statins should be discontinued. They may be restarted 7 days after the last dose of fusidic acid.
- In exceptional cases requiring prolonged systemic fusidic acid treatment, the need for a statin should be assessed on an individual basis and only undertaken with close medical supervision.
- Patients should be advised to seek medical advice immediately if they experience muscle weakness, pain or tenderness.
- Any muscle symptoms reported in patients who are prescribed statins should be followed up.